Luvixasertib (CFI-402257)
Product Specifications
CAS Number
1610759-22-2
Synonyms
Luvixasertib
Target
Serine/threonin kinase
Applications
Cell Cycle
Molecular Formula
C28H30N6O3
Additionnal Information
Luvixasertib (CFI-402257) is an inhibitor of threonine tyrosine kinase (TTK) with IC50 of 1.7 nM and Ki of 0.1 nM, respectively. It is a potential therapeutic for treating hepatocellular carcinoma that works directly by inhibiting cell-cycle checkpoints in cancer cells and indirectly by mobilizing immune cells from the tumor microenvironment.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC401073-500 1x 500 µL
HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740158-500 1x 500 µL
Cytokeratin 17 (E3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740485-100 1x 100 µL
ODC-1 (Ornithine Decarboxylase-1) (ODC1/485), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042083-500 1x 500 µL
CD86 (Dendritic Cells Maturation Marker) (rC86/1146), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040689-500 1x 500 µL
Cytokeratin 8 (K8.8), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details